Clinical Validation of AI-Powered PD-L1 Tumor Proportion Score Interpretation for Predicting Immune Checkpoint Inhibitor Response in NSCLC
Clinical Validation of AI-based Interpretation of PD-L1 Tumor Proportion Score in Predicting Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer In the field of tumor treatment and diagnosis, the assessment of PD-L1 (Programmed Death-Ligand 1) Tumor Proportion Score (TPS) is a critical task, especially in predicting the response ...